Kurzrock R - Search Results

1

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy.

Bevins NJ, Okamura R, Montesion M, Adashek JJ, Goodman AM, Kurzrock R. Bevins NJ, et al. Among authors: kurzrock r. J Immunother Precis Oncol. 2022 Sep 22;5(4):90-97. doi: 10.36401/JIPO-22-9. eCollection 2022 Nov. J Immunother Precis Oncol. 2022. PMID: 36483582 Free PMC article.

2

Targeting the FGF/FGFR axis and its co-alteration allies.

Uehara Y, Ikeda S, Kim KH, Lim HJ, Adashek JJ, Persha HE, Okamura R, Lee S, Sicklick JK, Kato S, Kurzrock R. Uehara Y, et al. Among authors: kurzrock r. ESMO Open. 2022 Dec;7(6):100647. doi: 10.1016/j.esmoop.2022.100647. Epub 2022 Nov 29. ESMO Open. 2022. PMID: 36455506 Free PMC article.

3

Of Mice, Not Men: When the Bench-to-Bedside Bridge Is Broken.

Nikanjam M, Kato S, Kurzrock R. Nikanjam M, et al. Among authors: kurzrock r. J Immunother Precis Oncol. 2022 Oct 6;5(4):87-89. doi: 10.36401/JIPO-22-X3. eCollection 2022 Nov. J Immunother Precis Oncol. 2022. PMID: 36483587 Free PMC article. No abstract available.

4

Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population.

Rosenberg S, Ben Cohen G, Kato S, Okamura R, Lippman SM, Kurzrock R. Rosenberg S, et al. Among authors: kurzrock r. Mol Oncol. 2023 Sep;17(9):1844-1856. doi: 10.1002/1878-0261.13383. Epub 2023 Mar 25. Mol Oncol. 2023. PMID: 36694946 Free PMC article.

5

PD-L1 gene amplification and focality: relationship with protein expression.

Jardim DL, Murugesan K, Elvin JA, Huang RSP, Kurzrock R. Jardim DL, et al. Among authors: kurzrock r. J Immunother Cancer. 2023 Feb;11(2):e006311. doi: 10.1136/jitc-2022-006311. J Immunother Cancer. 2023. PMID: 36849197 Free PMC article.

6

Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis.

Aaroe A, Kurzrock R, Goyal G, Goodman AM, Patel H, Ruan G, Ulaner G, Young J, Li Z, Dustin D, Go RS, Diamond EL, Janku F. Aaroe A, et al. Among authors: kurzrock r. Blood Adv. 2023 Aug 8;7(15):3984-3992. doi: 10.1182/bloodadvances.2022009013. Blood Adv. 2023. PMID: 36857436 Free PMC article.

7

Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology?

Gupta A, Kurzrock R, Adashek JJ. Gupta A, et al. Among authors: kurzrock r. Cancers (Basel). 2023 Mar 3;15(5):1578. doi: 10.3390/cancers15051578. Cancers (Basel). 2023. PMID: 36900367 Free PMC article. Review.

8

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics.

Tateo V, Marchese PV, Mollica V, Massari F, Kurzrock R, Adashek JJ. Tateo V, et al. Among authors: kurzrock r. Pharmaceuticals (Basel). 2023 Apr 19;16(4):614. doi: 10.3390/ph16040614. Pharmaceuticals (Basel). 2023. PMID: 37111371 Free PMC article. Review.

9

Challenges and prospects of CSF1R targeting for advanced malignancies.

Moeller A, Kurzrock R, Botta GP, Adashek JJ, Patel H, Lee S, Pabla S, Nesline MK, Conroy J, Sicklick JK, Kato S. Moeller A, et al. Among authors: kurzrock r. Am J Cancer Res. 2023 Jul 15;13(7):3257-3265. eCollection 2023. Am J Cancer Res. 2023. PMID: 37560003 Free PMC article.

10

Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.

Kondrashov A, Sapkota S, Sharma A, Riano I, Kurzrock R, Adashek JJ. Kondrashov A, et al. Among authors: kurzrock r. Pharmaceutics. 2023 Aug 19;15(8):2160. doi: 10.3390/pharmaceutics15082160. Pharmaceutics. 2023. PMID: 37631374 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

989 results

Search Page